Clinical Validation of Plasma p‐217tau in Neurological Diseases
Annals of Clinical and Translational Neurology · 2026
DOI: 10.1002/acn3.70359 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Takeshi Kawarabayashi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Dementia Research Center, Geriatrics Research Institute and Hospital, Maebashi, Japan. Hauptthemen laut MEDLINE: tau Proteins, Hydrocephalus, Normal Pressure, Alzheimer Disease, Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants for Scientific Research (C) from the Ministry of Education, Science, and Culture of Japan.
Abstract (Originalsprache)
Objective
Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Methods
Plasma p‐217tau levels were measured in 298 participants, consisting of 81 AD patients, 204 patients with 12 other neurological diseases, and 13 healthy and cognitively unimpaired controls (HCU), using an assay system from Meso Scale Diagnostics. Cerebrospinal fluid (CSF) tau and Aß levels were simultaneously evaluated in AD, amyotrophic lateral sclerosis (ALS), and idiopathic normal pressure hydrocephalus (iNPH).
Results
Plasma p‐217tau levels increased in AD with the clinical stage, but also in ALS and iNPH, leading to them having decreased sensitivity and specificity for diagnosing AD. No increases in plasma p‐217tau levels were seen in possible tauopathies or synucleinopathies. CSF and plasma p‐217tau levels were strongly correlated in AD, but not in ALS. The plasma p‐217tau/CSF p‐217tau ratio was inversely higher in ALS than in AD. Active and chronic denervation potentials were associated with plasma p‐217tau levels. In iNPH, plasma p‐217tau was associated with cognitive dysfunction, but not with gait disturbance or urinary incontinence. CSF p‐181tau, total tau, and Aß1‐40 levels and the Aß1‐40/1–42 ratio were reduced in iNPH.
Interpretation
ALS and iNPH are two major pitfalls for the clinical application of plasma p‐217tau as a biomarker of AD. Lower motor neuron injury in ALS and cognitive dysfunction in iNPH were both found to be associated with elevated plasma p‐217tau levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Dementia Research Center, Geriatrics Research Institute and Hospital, Maebashi, Japan.
- Department of Neurology, Gunma University Graduate School of Medicine, Maebashi, Japan.
- Department of Social Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Analytical Research Center, Mediford Corporation, Tokyo, Japan.
ORCID-Profile: Takeshi Kawarabayashi, Takumi Nakamura, Mikio Shoji
Förderung
- Grants for Scientific Research (C) from the Ministry of Education, Science, and Culture of Japan
Zitieren
APA
Kawarabayashi, T., Nakamura, T., Takahashi, R., Ueda, T., Kinoshita, S., Uchida, C., Sugawara, T., Hashimoto, K., Ishizawa, K., Amari, M., Kasahara, H., Ikeda, Y., Takatama, M., & Shoji, M. (2026). Clinical Validation of Plasma p‐217tau in Neurological Diseases. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70359
Vancouver
Kawarabayashi T, Nakamura T, Takahashi R, Ueda T, Kinoshita S, Uchida C, et al. Clinical Validation of Plasma p‐217tau in Neurological Diseases. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70359
BibTeX
@article{Kawarabayashi2026,
author = {Kawarabayashi, Takeshi and Nakamura, Takumi and Takahashi, Ryoma and Ueda, Tetsuya and Kinoshita, Seiji and Uchida, Chikage and Sugawara, Takashi and Hashimoto, Kentaro and Ishizawa, Kunihiko and Amari, Masakuni and Kasahara, Hiroo and Ikeda, Yoshio and Takatama, Masamitsu and Shoji, Mikio},
title = {Clinical Validation of Plasma p‐217tau in Neurological Diseases},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
doi = {10.1002/acn3.70359}
}
EUVIMED